logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Statistical bulletin 2007 search results

displaying all

Category Title
.
HSR HSR-0. References for needle and syringe programme information
HSR HSR-1. Number of syringe provision outlets and number of syringes (in thousands) exchanged, distributed or sold in 2005
HSR HSR-2. Year of introduction of needle and syringe programmes and types of programmes available in 2005
HSR HSR-3. Number of non-pharmacy needle and syringe programme points and number of syringes exchanged, distributed or sold 2002-2005
HSR HSR-4. Total number of pharmacy-based needle and syringe programmes and number of syringes exchanged or distributed 2002-2005
HSR HSR-5. Number of syringe vending machines and number of syringes distributed or sold 2002-2005
HSR HSR-6. Legal framework and practice of substitution treatment initiation
HSR HSR-7. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution in EU-27 and Norway, 2003 and 2005
HSR HSR-8. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT) and heroin-assisted treatment, including trials
HSR HSR-9. Consumption of methadone (kg) in 29 European countries, in the Unites States of America and total consumption worldwide, 1992 to 2005
HSR HSR-10. National substitution registries and other sources of data on substitution clients
HSR HSR-11. Estimated number of clients in methadone treatment in EU countries and Norway, 1993 - 2005
HSR HSR-1. Year of introduction of methadone maintenance and high dosage buprenorphine treatmentin 26 EU countries and Norway
HSR HSR-3. Number of opioid maintenance treatment clients as rate per 100 of the estimated number of problem opioid users, 2004 and 2005
HSR HSR-4. Estimated number of clients receiving opioid substitution treatment each year in EU-15, 1993-2005
SZR SZR-1. Number of cannabis resin seizures, 1995 to 2005
SZR SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2005
SZR SZR-3. Number of herbal cannabis seizures, 1995 to 2005
SZR SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2005
SZR SZR-5. Number of seizures of cannabis plants, 1995 to 2005
SZR SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2005
SZR SZR-7. Number of heroin seizures 1995 to 2005
SZR SZR-8. Quantities (kg) of heroin seized 1995 to 2005
SZR SZR-9. Number of cocaine seizures 1995 to 2005
SZR SZR-10. Quantities (kg) of cocaine seized 1995 to 2005
SZR SZR-11. Number of amphetamine seizures 1995 to 2005
SZR SZR-12. Quantities (kg) of amphetamine seized 1995 to 2005
SZR SZR-13. Number of ecstasy seizures 1995 to 2005
SZR SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2005
SZR SZR-15. Number of LSD seizures 1995 to 2005
SZR SZR-16. Quantities (units) of LSD seized 1995 to 2005
SZR SZR-17. Number of Methamphetamine seizures. 2001 to 2005
SZR SZR-18. Quantities (kg) of Methamphetamine seized. 2001 to 2005
SZR SZR-107. Number of heroin seizures 1985 to 2005
SZR SZR-108. Quantities (kg) of heroin seized 1985 to 2005
SZR SZR-109. Number of cocaine seizures 1985 to 2005
SZR SZR-110. Quantities (kg) of cocaine seized 1985 to 2005
SZR SZR-111. Number of amphetamine seizures 1985 to 2005
SZR SZR-112. Quantities (kg) of amphetamine seized 1985 to 2005
SZR SZR-113. Number of ecstasy seizures 1987 to 2005
SZR SZR-114. Quantities (tablets) of ecstasy seized 1987 to 2005
SZR SZR-115. Number of LSD seizures 1995 to 2005
SZR SZR-116. Quantities (units) of LSD seized 1995 to 2005
PPP PPP-1. Price of cannabis products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-1. Price of cannabis products at retail level, 2005 Part (ii) Sources of information
PPP PPP-2. Price of heroin at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-2. Price of heroin at retail level, 2005 Part (ii) Sources of information
PPP PPP-3. Price of cocaine products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-3. Price of cocaine products at retail level, 2005 Part (ii) Sources of information
PPP PPP-4. Price of synthetic drugs at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-4. Price of synthetic drugs at retail level, 2005 Part (ii) Sources of information
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) potency recorded, measured as percentage of THC content
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (ii) Sources of information
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (iii) Sampling frame/type of study
PPP PPP-6. Purity of heroin at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
PPP PPP-6. Purity of heroin at retail level, 2005 Part (ii) Sources of information
PPP PPP-6. Purity of heroin at retail level, 2005 Part (iii) Sampling frame/type of study
PPP PPP-7. Purity of cocaine products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
PPP PPP-7. Purity of cocaine products at retail level, 2005 Part (ii) Sources of information
PPP PPP-7. Purity of cocaine products at retail level, 2005 Part (iii) Sampling frame/type of study
PPP PPP-8. Purity of synthetic drugs at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) purity recorded
PPP PPP-8. Purity of synthetic drugs at retail level, 2005 Part (ii) Sources of information
PPP PPP-8. Purity of synthetic drugs at retail level, 2005 Part (iii) Sampling frame/type of study
PPP PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2000-2005
GPS GPS-0. Nationwide surveys among the general population: bibliographic references
GPS GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults (percentage)
GPS GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (ii) Survey methods
GPS GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
GPS GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
GPS GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
GPS GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
GPS GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
GPS GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part(i) Last month prevalence (percentage)
GPS GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part(ii) Frequency of use among all users in last month (percentage)
GPS GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults (percentage): last survey available for each Member State
GPS GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (ii) Survey methods: last survey available for each Member State
GPS GPS-9. Lifetime prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-10. Last year prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-11. Last year prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-12. Last month prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-13. Last month prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-14. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-15. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-16. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
GPS GPS-18. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
GPS GPS-19. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (ii) Germany
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iii) Spain
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iv) France
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) Italy
GPS GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (vi) Netherlands
GPS GPS-21. Methodological information for nation-wide surveys among the general population
GPS GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64 years old), young adults (aged 15 to 34 years old) and for the 15 to 24 years old age group, measured by national population surveys
GPS GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS GPS-3. Last month prevalence of cannabis among the age group of 15 to 24 years, measured by national surveys
GPS GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
GPS GPS-5. Last year prevalence of amphetamines among young adults, 15 to 34 and 15 to 24, measured by population surveys
GPS GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys
GPS GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS GPS-10. Last year prevalence of cannabis by age group in United Kingdom, measured by national population surveys
GPS GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available Part (i) Last year prevalence in some of the EU-15 Member States
GPS GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
GPS GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys
GPS GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
GPS GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (15 to 34 years)
GPS GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use – lifetime experience, last year and last month prevalence
GPS GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use – lifetime experience, last year and last month prevalence
GPS GPS-19. Comparison of drug use prevalence during last year by different user groups in the general population aged 15 to 34 – data for Spain, 1999
GPS GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA - last survey available for each country
GPS GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys
GPS GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
EYE EYE-0. School Surveys: Sources
EYE EYE-1. Recent school surveys (2003-2005): Lifetime prevalence (percentage) of psychoactive substance use among students aged 15-16 years old
EYE EYE-2. Recent school surveys (2003-2005): lifetime percentage prevalence (LTP) of psychoactive substance use and last month prevalence (LMP) of cannabis among students aged 17 to 18 years
EYE EYE-3. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15-16 years
EYE EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (i) Females
EYE EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (ii) Males
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (i) All students
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (i) Females
EYE EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (ii) Males
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (i) All students
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-1. Drug use among minors Part (i) Distribution of frequency of cannabis use sessions (percentage) according to age at first use among French population aged 17 years old who have ever used cannabis
EYE EYE-1. Drug use among minors Part (ii) Changes between 1995 and 2003 in recalled use of cannabis at or before age 13 (percentage points) as reported by 15- to 16-year-old school students.
EYE EYE-1. Drug use among minors Part (iii) Comparison of LTP (percentage) for inhalants/volatile substances between three different school student age groups in 3 countries
EYE EYE-2. Cocaine use among young people Part (i) Comparison of lifetime prevalence of cocaine use with perceived risk (percentage) among 15- to 16-year-old school students in 2003.
EYE EYE-2. Cocaine use among young people art (ii) Comparison of lifetime prevalence of cocaine use (percentage) and perceived availability among 15- to 16-year-old school students, 2003.
EYE EYE-2. Cocaine use among young people Part (iii) Comparison of LTP (percentage) for inhalants/volatile substances between three different school student age groups in 3 countries
PDU PDU-0. Prevalence of problem drug use at national and subnational level: bibliographic references
PDU PDU-1. Prevalence of problem drug use at national level: summary table, 2001-2005, rate per 1000 aged 15-64 Part (i) Overall problem drug use
PDU PDU-1. Prevalence of problem drug use at national level: summary table, 2001-2005, rate per 1000 aged 15-64 Part (ii) Injecting drug use
PDU PDU-2. Prevalence of problem drug use at national level - full listing of studies Part (i) Problem drug use
PDU PDU-2. Prevalence of problem drug use at national level - full listing of studies Part (ii) Injecting drug use
PDU PDU-3. Prevalence of problem drug use at subnational level - full list of studies Part (i) Problem drug users
PDU PDU-3. Prevalence of problem drug use at subnational level - full list of studies Part (ii) Injecting drug users
PDU PDU-4. Trends in injecting drug use - percentage current injecting among all clients entering treatment for primary drug heroin, 2001 to 2005
PDU PDU-1. Estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005 Part (i) Estimates of overall PDU
PDU PDU-1. Estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005 Part (ii) Estimates for problem opioid use
PDU PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005
PDU PDU-3. Percentage of new and of young injectors in samples of injecting drug users tested for HIV or HCV, studies from 2003 to 2005
PDU PDU-4. Estimated trends in the prevalence of overall problem drug use 2001 to 2005 (rate per 1000 population aged 15 to 64): Combined estimates per country
DUP DUP-0. Prevalence of drug use among prisoners - Sources and bibliographic references
DUP DUP-1. Prevalence of lifetime drug use among prisoners, 1995-2006
DUP DUP-2. Prevalence of lifetime injecting drug use among prisoners, 1995-2006
DUP DUP-3. Prevalence of drug use within prison among prisoners, 1995-2006
DUP DUP-4. Prevalence of injecting drug use within prison among prisoners, 1995-2006
DUP DUP-5. Prevalence (percentage) of drug use among prisoners in EU member states and Norway - full listing of studies
DUP DUP-1. Studies of lifetime prevalence of use of various drugs among prisoners in some EU Member States, 1999 to 2006
INF INF-0. Bibliographic references
INF INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
INF INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
INF INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
INF INF-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2005, (a) cases per million population and (b) number of cases
INF INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all cases with known risk factor Part (i) Notifications of hepatitis C related to IDU, 1992 to 2005
INF INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDUs and percentage of IDUs amongst all cases with known risk factor Part (ii) Notes and comments, 1992 to 2005
INF INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all notified cases with known risk factor Part (i) Notifications hepatitis B related to IDU, 1992 to 2005
INF INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDUs and percentage of IDUs amongst all notified cases having a known risk factor Part (ii) Notes and comments, 1992 to 2005
INF INF-7. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
INF INF-8. Prevalence of HIV infection (percentage) among injecting drug users - Data, 1991 to 2006
INF INF-9. Prevalence of HIV infection (percentage) among injecting drug users under age 25 - Data, 1991 to 2005
INF INF-10. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years) - Data, 1991 to 2005
INF INF-11. Prevalence of hepatitis C infection (percentage) among injecting drug users - Data, 1991 to 2005
INF INF-12. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25 - Data, 1991 to 2005
INF INF-13. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years) - Data, 1991 to 2005
INF INF-14. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users - Data, 1991 to 2005
INF INF-15. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users - Data, 1991 to 2005
INF INF-16. Estimated HIV prevalence among injecting drug users - selected country-specific studies
INF INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, 1996 to 2005
INF INF-2. HIV infections newly diagnosed in injecting drug users in the most severely affected EU countries, Russian Federation and Ukraine, by year of report 1996-2005, cases per million population
INF INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage Part (i) All injecting drug users, 2004 - 2005
INF INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage Part (ii) Young injecting drug users (aged under 25), 2004 - 2005
INF INF-4. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2005
INF INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage Part (i) All injecting drug users, 2004 - 2005
INF INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage Part (ii) Young injecting drug users (aged under 25), 2004 - 2005
INF INF-7. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users, 2001 to 2005
INF INF-8. Notified cases of hepatitis C related to injecting drug use: proportion injecting drug users among all cases with risk factor information, 2001 to 2005
INF INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2004 to 2005, where data are available Part (i) Percentage positive for ever infected (aHBc)
INF INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2004 to 2005, where data are available Part (ii) Percentage positive for current infection (HBsAg)
INF INF-11. Notified cases of hepatitis B in injecting drug users: proportion injecting drug users among hepatitis B notifications with risk factor information, 2001 to 2005
DRD DRD-0. Drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, sources and bibliographic references
DRD DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions Part (i) 2005 or last year with available information (demographic characteristics)
DRD DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions Part (ii) 2005 or last year with available information (toxicology and numbers by selected age groups)
DRD DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions Part (iii) 1990 or closest year with available information
DRD DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (i) Total drug-related deaths, 1990 to 2005
DRD DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (ii) Male drug-related deaths, 1990 to 2005
DRD DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (iii) Female drug-related deaths, 1990 to 2005
DRD DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (iv) Total drug-related deaths under the age of 25 years, 1990 to 2005
DRD DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (v) Totals and indexes, 1990 to 2005
DRD DRD-3. Number of acute drug-related deaths recorded in EU Member States, Norway and candidate countries according to EMCDDA standard definition 'Selection B', 1990 to 2005
DRD DRD-4. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to EMCDDA standard definition 'Selection D', 1990 to 2005
DRD DRD-5. Mortality due to drug-related deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (i) Population mortality rates, 2005 or last year with available information
DRD DRD-5. Mortality due to drug-related deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (ii) Proportional mortality due to drug-related deaths, 2005 or last year with available information
DRD DRD-1. Reitox national reports 2006, taken from national mortality registries or special registries (forensic or police). Based on national definitions as presented in 2007 statistical bulletin, methodological notes for drug-related deaths
DRD DRD-2. Proportion of acute drug-related deaths occurring under the age of 25 years in 2003
DRD DRD-3. Trends in mean age of acute drug-related deaths in some of the EU-15 Member States, 1990 to 2005
DRD DRD-4. Trends in mean age of acute drug-related deaths in some new Member States of the EU 1990 to 2005
DRD DRD-5. lndexed trends in acute drug-related deaths and in the numbers of deaths under 25 years old Part (i) Changes between 2000 and 2003
DRD DRD-5. lndexed trends in acute drug-related deaths and in the numbers of deaths under 25 years old Part (ii) Indexed trend in the new Member States 1990-2005
DRD DRD-6. Indexed overall trends for males and females in acute drug-related deaths in the EU-15 member states and Norway, 1990 to 2005
DRD DRD-8. Indexed long term trend in acute drug-related deaths in the EU (old Member States and Norway), 1985 to 2005
DRD DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average) Part (i) Some EU countries and Norway, 1990 to 2005
DRD DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average) Part (ii) Some EU countries, 1990 to 2005
DRD DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average) Part (iii) Index in some Member States, 1985 to 2005
DRD DRD-10. Mean age of acute drug-related deaths in EU countries, last year with available data
DRD DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (i) Index in some Member States, 1985 to 2005
DRD DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (ii) Index in some Member States, 1985 to 2005
DRD DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (iii) Index in some Member States, 1985 to 2005
DRD DRD-7. Proportional change in acute drug-related deaths in the EU Member States Part (i) Changes between 2000 and 2003
DRD DRD-7. Proportional change in acute drug-related deaths in the EU Member States Part (ii) Changes between 2003 and 2004/5
DLO DLO-1. Number of reports for drug law offences. 1995 to 2005
DLO DLO-2. Offence types involved in reports for drug law offences: percentage of all reports for drug law offences
DLO DLO-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences
DLO DLO-4. Number of drug law offences related to drug use or possession for use, 1999 to 2005
DLO DLO-5. Percentage of total drug law offences that are related to drug use or possession for use, 1996 to 2005
DLO DLO-6. Cannabis-related offences: as percentage of all drug law offences, 1996 to 2005
DLO DLO-7. Heroin-related offences as percentage of all drug law offences, 1996 to 2005
DLO DLO-8. Number of reports for drug law offences 1985 to 2005
DLO DLO-1. Drug law offences in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-1. Drug law offences in Europe, 2000-2005 Part (ii) new EU Member States and Turkey
DLO DLO-2. Cannabis-related offences in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-2. Cannabis-related offences in Europe, 2000-2005 Part (ii) new EU Member States and Turkey
DLO DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005 Part (ii) New Member States and Turkey
DLO DLO-4. Cocaine-related offences in Europe, 2000-2005 Part (i) EU-15 Member states and Norway
DLO DLO-4. Cocaine-related offences in Europe, 2000-2005 Part (ii) New EU Member States and Turkey
DLO DLO-5. Heroin-related offences in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-5. Heroin-related offences in Europe, 2000-2005 Part (ii) new EU Member States and Turkey
DLO DLO-6. Indexed trends in reports for drug law offences in EU member states 2000-2005
TDI TDI-1. Data sources for data on clients entering treatment in 2005
TDI TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005 Part (i) Total numbers of new clients entering treatment
TDI TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005 Part (ii) Total numbers of all clients entering treatment
TDI TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005 Part (iii) Numbers of treatment units covered for reporting clients entering treatment
TDI TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005 Part (iv) Types of units covered for reporting clients entering treatment
TDI TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005 Part (i) Percent of new clients using heroin
TDI TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005 Part (ii) Percent of new clients using cocaine
TDI TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005 Part (iii) Percent of new clients using cannabis
TDI TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005 Part (iv) Percent of new clients using stimulants (amphetamines and MDMA)
TDI TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (i) Demographics
TDI TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (ii) Primary drug type used (percent of new clients using) and of those, the percent injecting it
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (i) Demographics of all clients entering treatment
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (ii) Primary drug type used by clients (percent of all clients) and of those, the percent injecting it
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (iii) Demographics of all men entering treatment
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (iv) Demographics of all women entering treatment
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (v) Primary drug type used by male clients (percent of all male clients)
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (vi) Primary drug type used by female clients (percent of all female clients)
TDI TDI-6. Incidence of treatment demands for drug use: new clients entering treatment in 2005 (rate per 100,000 population)
TDI TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data Part (i) Number of new and all clients entering treatment: by the treatment demand indicator schedule reports in 2005, by type of treatment centre
TDI TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data Part (ii) Outpatient treatment centres
TDI TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data Part (iii) Inpatient treatment centres
TDI TDI-8. New and all clients entering treatment for primary use of amphetamines, ecstasy and other non-cocaine stimulants in 2005 for countries supplying data Part(i) All clients of all treatment centres reported for the country
TDI TDI-8. New and all clients entering treatment for primary use of amphetamines, ecstasy and other non-cocaine stimulants in 2005 for countries supplying data Part(ii) New clients of all treatment centres reported for the country
TDI TDI-9. Clients entering outpatient treatment: mean age and gender distribution among new and all clients in 2005
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (i) Distribution of new outpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (ii) Distribution of new outpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (iii) Distribution of all outpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (iv) Distribution of all outpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (v) Distribution of new inpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (vi) Distribution of new inpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (vii) Distribution of all inpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (viii) Distribution of all inpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (i) Distribution of new outpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (ii) Distribution of new outpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (iii) Distribution of all outpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (iv) Distribution of all outpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (v) Distribution of new inpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (vi) Distribution of new inpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (vii) Distribution of all inpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (viii) Distribution of all inpatient clients by primary drug for each age group
TDI TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data Part (i) New clients entering outpatient treatment
TDI TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data Part (ii) All clients entering outpatient treatment
TDI TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data Part (iii) New clients entering inpatient treatment
TDI TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data Part (iv) All clients entering inpatient treatment
TDI TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data Part (i) New clients entering outpatient treatment
TDI TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data Part (ii) All clients entering outpatient treatment
TDI TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data Part (iii) New clients entering inpatient treatment
TDI TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data Part (iv) All clients entering inpatient treatment
TDI TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data Part (i) New clients entering outpatient treatment
TDI TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data Part (ii) All clients entering outpatient treatment
TDI TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data Part (iii) New clients entering inpatient treatment
TDI TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data Part (iv) All clients entering inpatient treatment
TDI TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data Part (i) New clients entering outpatient treatment
TDI TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data Part (ii) All clients entering outpatient treatment
TDI TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data Part (iii) New clients entering inpatient treatment
TDI TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data Part (iv) All clients entering inpatient treatment
TDI TDI-16. New clients entering outpatient treatment: distribution (percent) by source of referral in 2005 for countries supplying data
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (i) Percentage amongst new clients with opioids as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (ii) Percentage amongst new clients with cocaine (HCl and crack) as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (iii) Percentage amongst new clients with stimulants (other than cocaine) as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (iv) Percentage amongst new clients with hypnotics and sedatives as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (v) Percentage amongst all clients with opioids as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (vi) Percentage amongst all clients with cocaine (HCl and crack) as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (vii) Percentage amongst all clients with stimulants (other than cocaine) as primary drug
TDI TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 Part (viii) Percentage amongst all clients with hypnotics and sedatives as primary drug
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (i) Percentage distribution amongst new outpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (ii) Percentage distribution amongst all outpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (iii) Percentage distribution amongst new inpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (iv) Percentage distribution amongst all inpatient clients
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (i) New clients entering outpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (ii) All clients entering outpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (iii) New clients entering inpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (iv) All clients entering inpatient treatment
TDI TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population Part (i) New clients entering outpatient treatment
TDI TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population Part (ii) All clients entering outpatient treatment
TDI TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population Part (iii) New clients entering inpatient treatment
TDI TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population Part (iv) All clients entering inpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (i) Gender ratio (ratio of males to females) among new clients entering outpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (ii) Gender ratio (ratio of males to females) among all clients entering outpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (iii) Gender ratio (ratio of males to females) among new clients entering inpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (iv) Gender ratio (ratio of males to females) among all clients entering inpatient treatment
TDI TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data Part (i) Outpatient centres
TDI TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data Part (ii) Inpatient centres
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (i) Most frequent combination of the primary drug with the stated types of secondary drug (percentages)
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data Part(i) All clients entering treatment by percentage of Outpatient and Inpatient treatment
TDI TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data Part(ii) New clients entering treatment by percentage of Outpatient and Inpatient treatment
TDI TDI-25. Age distribution (column percentage) by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2005 for countries supplying data
TDI TDI-26. Number of all clients <15, 15-19, >19 years old by type of treatment centre and percentual (column) distribution in 2005 for countries supplying data
TDI TDI-27. All clients under 15, 15-19 and >19 entering treatment in 2005 for those countries supplying data
TDI TDI-28. Minor age groups: total number and percentage among all and new clients entering treatment in 2005 Part (i) percentage distribution of new clients by country
TDI TDI-29. Gender distrbution of all outpatient clients by three age groups in 2005 for those coutnries supplying data
TDI TDI-30. Trends in minors 1999 to 2005 Part (i) Number of all clients with age under 15
TDI TDI-30. Trends in minors 1999 to 2005 Part (iii) Number of all clients with age between 15 and 19
TDI TDI-30. Trends in minors 1999 to 2005 Part (iv) Percentage of all clients with age between 15 and 19
TDI TDI-30. Trends in minors 1999 to 2005 Part (v) Number of all clients with age more than 19
TDI TDI-30. Trends in minors 1999 to 2005 Part (vi) Percentage of all clients with age more than 19
TDI TDI-31. Gender ratio (male to female) in minors for those coutries supplying data for 2005
TDI TDI-101. Trends in gender distribution among new clients enering treatement from 1992 to 2005 (expressed as males / females ratio)
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opioids as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opioids as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile inhalants as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opioids as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile inhalants as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opioids as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile inhalants as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
.
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (v) Number of clients using volatile/inhalants as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005 Part (i) Percentage amongst new clients with cocaine HCl as primary drug
TDI TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005 Part (ii) Percentage amongst new clients with crack as primary drug
TDI TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005 Part (iii) Percentage amongst all clients with cocaine HCl as primary drug
TDI TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005 Part (iv) Percentage amongst all clients with crack as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (i) Percentage distribution amongst new clients with opioids as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (ii) Percentage distribution amongst all clients with opioids as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (i) Percentage distribution amongst new clients with opioids as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (ii) Percentage distribution amongst all clients with opioids as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
TDI TDI-113. New and all clients entering outpatient treatment for primary use of amphetamines, ecstasy and other stimulants in 2005 for countries supplying data Part(i) New clients
TDI TDI-113. New and all clients entering outpatient treatment for primary use of amphetamines, ecstasy and other stimulants in 2005 for countries supplying data Part(ii) All clients
TDI TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005 Part(i) Percentage among all clients entering treatment for opioids use from all clients entering treatment
TDI TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005 Part (ii) Percentage among new clients entering treatment for opioids use from all new clients entering treatment
TDI TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005 Part (iii) Number and percentage among all clients entering treatment
TDI TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005 Part(iv) Number and percentage among new client entering treatment
TDI TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data Part (i) Among all clients entering outpatient treatment
TDI TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data Part (ii) Among new clients entering outpatient treatment
TDI TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data Part (iii) Among all clients entering treatment (all types of treatment)
TDI TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data Part (iv) Among new clients entering treatment (all types of treatment)
TDI TDI-116. Secondary drug distribution among all clients entering outpatient treatment with primary drug: amphetamines and ecstasy in 2005 for countries supplying data
TDI TDI-117. Mean age of all clients entering outpatient and inpatient treatment for amphetamines and ecstasy for countries supplying data in 2005
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (i) Combination of the primary drug with the stated types of secondary drug (percentages) - overall / EU summary
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (ii) All clients with cocaine HCl as primary drug type: numbers of episodes reporting the stated drugs as secondary
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (iii) All clients with crack as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (iv) All clients with opioids as primary drug type: number of episodes reporting cocaine HCl and crack as secondary
TDI TDI-119. Percentage proportion of all clients treated on opioid misuse from all treated clients within the treatment centres by type of treatment centre for countries supplying data in 2005
TDI TDI-120. Mean age and gender ratio (males to females) among all clients entering outpatient treatment centres in 2005 for those countries supplying data
TDI TDI-121. Frequency of use of primary drug: cocain HCl and crack among all outpatient clients in 2005 for countries supplying data
TDI TDI-122. All outpatient clients under 15 entering treatment by primary drug in 2005 for those countries supplying data
TDI TDI-123. All drug clients under 15 entering drug treatment in 2005 in 6 EU countries + Turkey
TDI TDI-124. All drug clients under 15 by year of age entering drug treatment in 2005 in 6 EU countries + Turkey
TDI TDI-125. Primary drug of consumption among all drug clients under 15 entering drug treatment in 2005 in 6 EU countries + Turkey
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 1999 to 2005 Part (i) Trend in distribution by primary drug (percentage)
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 1999 to 2005 Part (ii) Trend in numbers of clients by primary drug
TDI TDI-3. Estimated numbers of all clients asking treatment by heroin, cocaine, cannabis, other stimulants (percent): overall EU trend in from 1999 to 2005 Part (i) Trend in percentages of clients by primary drug
TDI TDI-3. Estimated numbers of all clients asking treatment by heroin, cocaine, cannabis, other stimulants (percent): overall EU trend in from 1999 to 2005 Part (ii) Trend in numbers of clients by primary drug
TDI TDI-2. New and all clients entering treatment in 2005 by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs (21 countries- 20 EU + TR - included for all clients and 22 countries - 21 EU + TK - for new clients)
TDI TDI-5. Trends in cocaine and in the total number of new clients from 1999 to 2005 in 20 countries
TDI TDI-6. New and all outpatient clients by age group in 2005 for those countries supplying data
TDI TDI-7. Distribution according to primary drug of all clients aged under 15 entering treatment - EU summary for countries supplying data in 2005
TDI TDI-8. Age distribution of all clients 10-14 years entering treatment for cannabis and volatile/inhalant drugs - EU overall summary for countries supplying data in 2005
TDI TDI-9. New treatment demand for drug use: (rate per 100,000 population in 2006) and reporting coverage of treatment centers
TDI TDI-10. Percentage of clients injecting opoids and cocaine among all outpatient clients by country in 2005
TDI TDI-11. Numbers of clients reported entering treatment for any drug: overall EU trends by age group for all clients entering treatment 1999-2005
TDI TDI-12. Gender ratio of all outpatient clients by three age groups in 2005: overall EU
TDI TDI-13. Distribution of all clients entering treatment by primary drug at treatment in 2005 or most recent year available
TDI TDI-14. Percent using cocaine as primary drug among new clients entering treatment, 1993 to 2005 - countries reporting in excess of 5% of new clients
TDI TDI-4. Male to female ratio among all clients entering outpatient treatment by main drug in 2005
GPS GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available Part (ii) Last year prevalence in some new EU Member States
HSR HSR-2. Clients in substitution treatment per 100.000 adult population (2003 - 2005)
TDI TDI-28. Minor age groups: total number and percentage among all and new clients entering treatment in 2005 Part (ii) percentage distribution of all clients by country
TDI TDI-30. Trends in minors 1999 to 2005 Part (ii) Percentage of all clients with age under 15
PDU PDU-5. Studies used in focused analysis of proportions of young (aged less than 25 years) and new (injecting for less than 2 years) IDUs among samples tested for infectious diseases Part (i) Summary of prevalence studies in IDUs with available data on distribution by age
PDU PDU-5. Studies used in focused analysis of proportions of young (aged less than 25 years) and new (injecting for less than 2 years) IDUs among samples tested for infectious diseases Part (ii) Summary of prevalence studies in IDUs with available data on distribution by years of injecting
DRD DRD-6. Methodological features of drug-related deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5 Part 1)
DRD DRD-7. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (i) Total drug-related deaths, 1985 to 2005
DRD DRD-7. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions Part (ii) Totals and indexes, 1985 to 2005

Page last updated: Tuesday, 20 March 2012